Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2012-01-06
Target enrollment:
Participant gender:
Summary
RATIONALE: Aurora kinase inhibitor AT9283 (AT9283) may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of AT9283 in treating
patients with advanced or metastatic solid tumors or non-Hodgkin's lymphoma.